Gilead Palo Alto v. EMS S/A: Appeal Dismissed in Nucleoside Patent Dispute
Gilead Palo Alto, Inc. asserted Brazilian patent BR122018015050B1, covering phosphated nucleoside derivatives and their pharmaceutical compositions, against generic pharmaceutical company EMS S/A. The Court of Justice of São Paulo dismissed the appeal, closing the matter at this court level without a merits ruling on infringement.
Gilead’s appeal against Brazilian generics rival ends without merits ruling
Gilead Palo Alto, Inc., the IP holding entity within the Gilead Sciences group, brought an infringement action before the Court of Justice of São Paulo against EMS S/A, one of Brazil’s largest generic pharmaceutical manufacturers. The asserted patent, BR122018015050B1, protects phosphated nucleoside derivatives and pharmaceutical compositions thereof — a class of compounds central to antiviral and antiretroviral drug development.
The Court of Justice of São Paulo dismissed the appeal, bringing the matter to a close at this appellate level as of 21 June 2024. A dismissal on these terms indicates the court declined to consider the substance of the infringement arguments, terminating the appeal on procedural or standing grounds rather than adjudicating whether EMS S/A’s products fell within the scope of BR122018015050B1.
The absence of a merits ruling leaves the underlying infringement question formally unresolved in this proceeding. The relatively swift closure suggests procedural deficiencies may have undermined the appeal before it reached substantive review. Whether Gilead pursues further enforcement actions in Brazil — including separate district-level filings or regulatory data exclusivity challenges — remains outside the scope of this public record.
Filing to Appeal Dismissed in 0 days
Case closed 21 June 2024 at the Court of Justice of São Paulo
Appeal dismissed: what the ruling means for Gilead and EMS S/A
Dismissal without merits: what ‘appeal dismissed’ means
An appeal dismissal at the Court of Justice of São Paulo terminates the appellate proceeding without the court reviewing the substance of the infringement arguments. The lower-level outcome — whatever it was — is not disturbed by an appellate ruling on the merits. The dismissal typically reflects a procedural defect, lack of standing, or non-compliance with appellate requirements, not a determination that infringement did or did not occur.
Procedural terminationNo appellate victory for Gilead on the infringement claim
Gilead Palo Alto does not obtain an infringement finding through this appeal. The dismissal means the patent’s enforceability against EMS S/A’s specific products has not been confirmed by this court. BR122018015050B1 remains in force as a granted Brazilian patent, but Gilead would need to pursue fresh or parallel proceedings to obtain a substantive ruling on infringement against EMS S/A.
No infringement findingEMS S/A avoids an adverse ruling — for now
The dismissal benefits EMS S/A in the immediate term: no court has found its phosphated nucleoside products infringe BR122018015050B1. However, a procedural dismissal does not constitute a finding of non-infringement or patent invalidity. EMS S/A remains exposed to future enforcement actions by Gilead in Brazil, and the underlying patent continues to pose a commercial risk to its product line in this therapeutic class.
No non-infringement rulingNucleoside patent risk in Brazil remains live for generics sector
The dismissal resolves nothing substantively about the scope or enforceability of Gilead’s nucleoside composition patent in Brazil. For generic manufacturers operating in the antiretroviral and antiviral space, BR122018015050B1 continues to represent a potential enforcement risk. The outcome suggests procedural strategy matters significantly in Brazilian pharmaceutical IP litigation — a lesson relevant to both originator and generics companies navigating TJSP proceedings.
Ongoing patent risk in BrazilFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Gilead Palo Alto, Inc. | Company | Pharmaceutical IP holding entity — holder of BR122018015050B1 (phosphated nucleoside derivatives)Search in Eureka ↗ |
| Defendant | EMS S/A. | Individual | EMS S/A — major Brazilian generic pharmaceutical manufacturer and distributorSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The verdict phrase ‘I DISMISS the appeal’ is a procedural disposition — the Court of Justice of São Paulo declined to entertain the appeal on its merits. This language is consistent with a finding that the appeal failed to satisfy mandatory admissibility requirements under Brazilian civil procedure, such as proper standing, timeliness, or prescribed formalities. It does not constitute any ruling on whether EMS S/A infringed BR122018015050B1, nor does it affect the patent’s validity or granted status. Both parties’ substantive positions on infringement remain legally unresolved by this decision.
BR122018015050B1 — Phosphated Nucleoside Derivatives & Pharmaceutical Compositions
BR122018015050B1 is a Brazilian patent protecting phosphated nucleoside derivatives and pharmaceutical compositions containing them. Phosphated nucleoside derivatives are a chemically significant class of compounds that underpin several antiviral and antiretroviral therapies, including treatments for HIV and hepatitis. The patent’s ‘B1’ designation indicates it has passed substantive examination and been granted by the INPI (Brazilian National Institute of Industrial Property), conferring enforceable rights against unauthorised manufacture, use, or sale in Brazil.
For Gilead Sciences — a company whose commercial portfolio is heavily anchored in nucleoside and nucleotide analogue antiviral drugs — this patent represents a strategically critical asset in one of Latin America’s largest pharmaceutical markets. Brazil’s government has historically issued compulsory licences for HIV drugs, making patent enforcement in this category commercially and politically sensitive. Generic manufacturers active in the antiretroviral space, including EMS S/A, face ongoing FTO exposure while this patent remains in force.
Should your team run an FTO against BR122018015050B1?
Any company developing, manufacturing, or commercialising phosphated nucleoside derivatives or antiviral pharmaceutical compositions in Brazil should treat BR122018015050B1 as a live FTO risk. The dismissal of this appeal does not narrow or extinguish Gilead’s rights — the patent remains granted and enforceable. Product teams launching nucleoside-class antivirals or antiretrovirals in the Brazilian market without a current FTO opinion face material legal exposure.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to run structured freedom-to-operate assessments against BR122018015050B1 and related Gilead nucleoside patents across LATAM jurisdictions. Eureka can identify claim overlaps with your compound pipeline, surface family members active in adjacent markets, and flag prosecution history relevant to claim scope — giving your team the intelligence needed before market entry decisions are finalised.
Run a freedom-to-operate analysis on BR122018015050B1 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical patent infringement cases at Brazilian courts
Cases involving pharmaceutical composition patent enforcement and appeal dismissals at the Court of Justice of São Paulo, with a focus on antiviral and nucleoside-class disputes.
What this case signals for pharmaceutical IP enforcement in Brazil
A procedural dismissal at TJSP leaves the core patent dispute unresolved — and the competitive risk for nucleoside-class generics in Brazil intact.
Procedural compliance is decisive in Brazilian appellate patent actions
This dismissal, without any merits ruling, underscores that appellate procedural requirements at the Court of Justice of São Paulo are strictly applied. Patent holders and defendants alike must ensure rigorous compliance with Brazilian appellate rules — a defective filing can extinguish an otherwise viable infringement or defence argument before it is heard.
BR122018015050B1 remains enforceable and commercially relevant
The dismissal does not invalidate or narrow Gilead’s patent. Generic manufacturers in the phosphated nucleoside space — particularly those active in Brazil’s antiretroviral market — should treat this patent as an ongoing FTO risk. Monitoring Gilead’s enforcement activity and any ANS regulatory filings in Brazil is advisable for product teams in this therapeutic area.
Gilead v EMS — key questions answered
The Court of Justice of São Paulo dismissed the appeal in case 2060285-85.2024.8.26.0000, closing the matter on 21 June 2024 without a ruling on the merits of the infringement claim. No finding of infringement or non-infringement was made regarding BR122018015050B1.
No. A procedural dismissal of the appeal is not a ruling on infringement. The court did not examine whether EMS S/A’s products fall within the claims of BR122018015050B1. The patent remains granted and enforceable, and Gilead could pursue further proceedings in Brazil.
BR122018015050B1 protects phosphated nucleoside derivatives and pharmaceutical compositions thereof — a class of compounds central to antiviral and antiretroviral drug development. Brazil is a major market for HIV and hepatitis treatments, making this patent strategically significant for both originator and generic pharmaceutical companies operating there.
At the Court of Justice of São Paulo, an appeal dismissed without merits review typically indicates a procedural deficiency — such as a standing issue, untimely filing, or non-compliance with appellate formalities. The lower court decision is not affirmed or reversed; it simply stands as-is. The core dispute remains unresolved at the appellate level.
Yes. The dismissal of this appeal does not affect the patent’s validity or scope. Generic manufacturers active in the phosphated nucleoside and antiviral pharmaceutical space in Brazil should monitor Gilead’s enforcement activity, conduct FTO assessments against BR122018015050B1, and track any related INPI proceedings or compulsory licence developments that could affect market access.
PatSnap Eureka searches patents and litigation data to answer instantly.